Meg Tirrell

And it's the same problem for GLP-1.

Yeah.

It doesn't have time, essentially, to act in the ways that it needs to in our body as a medicine.

So

Novo Nordisk had to essentially develop a technology to enable it to be swallowed and so that our body could actually take it up as a medicine.

And interestingly, the technology is called SNAC.

Really?

It's like S-N-A-C.

Yeah.

I cannot remember what it stands for.

But it essentially sort of buffers it and enables it to get into our cells in a way that, you know, it gets metabolized.

But for that reason, the Wagovi pill that they just got approved, you know, essentially at the end of 2025 and

It went on the market in January.

You have to take it first thing in the morning, 30 minutes before eating or drinking much water.

You can have like four ounces of water with it.

And you have to wait before taking other medicines because it just changes the sort of metabolism of everything.

So that was sort of tricky.

And I think they were very proud of the fact that they engineered this to be able to work as a pill.

But then you have Eli Lilly, which developed a small molecule version of GLP-1 or for glipron.

Now it has a brand name, Foundeo.